A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Clinical trial NCT04274907 · TERMINATED
Trial details
- NCT number
- NCT04274907
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-30
- Primary completion
- 2021-02-02
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.